Literature DB >> 8735628

Rat striatal muscarinic receptors coupled to the inhibition of adenylyl cyclase activity: potent block by the selective m4 ligand muscarinic toxin 3 (MT3).

M C Olianas1, A Adem, E Karlsson, P Onali.   

Abstract

1. In rat striatal membranes, muscarinic toxin 3 (MT3), a selective ligand of the cloned m4 receptor subtype, antagonized the acetylcholine (ACh) inhibition of forskolin- and dopamine D1 receptor-stimulated adenylyl cyclase activities with pA2 values of 8.09 and 8.15, respectively. 2. In radioligand binding experiments, MT3 increased the Kd but did not change the Bmax value of [3H]-N-methylscopolamine (3H]-NMS) binding to rat striatal muscarinic receptors. The toxin displaced the major portion of the [3H]-NMS binding sites with a Ki of 8.0 nM. 3. In rat myocardium, MT3 antagonized the ACh inhibition of adenylyl cyclase with a Ki value of 860 nM. 4. In rat cerebral cortical membranes prelabelled with [3H]-myo-inositol, MT3 counteracted the methacholine stimulation of [3H]-inositol phosphates formation with a Ki value of 113 nM. 5. The present study shows that MT3 is a potent antagonist of the striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity. This finding provides strong evidence for the classification of these receptors as pharmacologically equivalent to the m4 gene product (M4). On the other hand, the weaker potencies of MT3 in antagonizing the muscarinic responses in cerebral cortex and in the heart are consistent with the reported lower affinities of the toxin for the cloned m1 and m2 receptor subtypes, respectively.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8735628      PMCID: PMC1909614          DOI: 10.1111/j.1476-5381.1996.tb15400.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  The striatum and cerebral cortex express different muscarinic receptor mRNAs.

Authors:  M R Brann; N J Buckley; T I Bonner
Journal:  FEBS Lett       Date:  1988-03-28       Impact factor: 4.124

2.  Differential regulation of PI hydrolysis and adenylyl cyclase by muscarinic receptor subtypes.

Authors:  E G Peralta; A Ashkenazi; J W Winslow; J Ramachandran; D J Capon
Journal:  Nature       Date:  1988-08-04       Impact factor: 49.962

3.  Pirenzepine distinguishes between muscarinic receptor-mediated phosphoinositide breakdown and inhibition of adenylate cyclase.

Authors:  D W Gil; B B Wolfe
Journal:  J Pharmacol Exp Ther       Date:  1985-03       Impact factor: 4.030

4.  A highly sensitive adenylate cyclase assay.

Authors:  Y Salomon; C Londos; M Rodbell
Journal:  Anal Biochem       Date:  1974-04       Impact factor: 3.365

5.  Localization of a family of muscarinic receptor mRNAs in rat brain.

Authors:  N J Buckley; T I Bonner; M R Brann
Journal:  J Neurosci       Date:  1988-12       Impact factor: 6.167

6.  Toxins from the venom of the green mamba Dendroaspis angusticeps that inhibit the binding of quinuclidinyl benzilate to muscarinic acetylcholine receptors.

Authors:  A Adem; A Asblom; G Johansson; P M Mbugua; E Karlsson
Journal:  Biochim Biophys Acta       Date:  1988-03-11

7.  Ligand: a versatile computerized approach for characterization of ligand-binding systems.

Authors:  P J Munson; D Rodbard
Journal:  Anal Biochem       Date:  1980-09-01       Impact factor: 3.365

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum.

Authors:  M C Olianas; P Onali; N H Neff; E Costa
Journal:  J Neurochem       Date:  1983-11       Impact factor: 5.372

10.  Adenylate cyclase activity of synaptic membranes from rat striatum. Inhibition by muscarinic receptor agonists.

Authors:  M C Olianas; P Onali; N H Neff; E Costa
Journal:  Mol Pharmacol       Date:  1983-03       Impact factor: 4.436

View more
  16 in total

1.  Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice.

Authors:  J Gomeza; L Zhang; E Kostenis; C Felder; F Bymaster; J Brodkin; H Shannon; B Xia; C Deng; J Wess
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

2.  Cholinergic modulation of neostriatal output: a functional antagonism between different types of muscarinic receptors.

Authors:  E Galarraga; S Hernández-López; A Reyes; I Miranda; F Bermudez-Rattoni; C Vilchis; J Bargas
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

3.  Involvement of the transmitter systems of the neostriatum in automation of motor skills in dogs.

Authors:  K B Shapovalova
Journal:  Neurosci Behav Physiol       Date:  2006-02

4.  M1 muscarinic receptors contribute to, whereas M4 receptors inhibit, dopamine D1 receptor-induced [3H]-cyclic AMP accumulation in rat striatal slices.

Authors:  Enrique Sánchez-Lemus; José-Antonio Arias-Montaño
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

5.  Muscarinic receptors of the neostriatum--their role in controlling operant behavior in dogs.

Authors:  K B Shapovalova
Journal:  Neurosci Behav Physiol       Date:  2002 Jul-Aug

6.  Adrenoceptor activity of muscarinic toxins identified from mamba venoms.

Authors:  K Näreoja; J P Kukkonen; S Rondinelli; D M Toivola; J Meriluoto; J Näsman
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

7.  Expression and localization of muscarinic receptors in P19-derived neurons.

Authors:  D Parnas; E Heldman; L Branski; N Feinstein; M Linial
Journal:  J Mol Neurosci       Date:  1998-02       Impact factor: 3.444

8.  Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice.

Authors:  Lene S Schmidt; Morgane Thomsen; Pia Weikop; Ditte Dencker; Jürgen Wess; David P D Woldbye; Gitta Wortwein; Anders Fink-Jensen
Journal:  Psychopharmacology (Berl)       Date:  2011-03-05       Impact factor: 4.530

9.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

10.  Operant behavior in conditions of activation and blockade of neostriatal muscarinic receptors.

Authors:  K B Shapovalova; T A Dyubkacheva; V N Chikhman; D A Mysovskii; Yu V Kamkina
Journal:  Neurosci Behav Physiol       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.